{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05346484",
            "orgStudyIdInfo": {
                "id": "CF33-hNIS-002"
            },
            "organization": {
                "fullName": "Imugene Limited",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors",
            "officialTitle": "A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Metastatic or Advanced Solid Tumors (MAST).",
            "acronym": "MAST",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-hnis-vaxinia-an-oncolytic-virus-as-monotherapy-or-in-combination-with-pembrolizumab-in-adults-with-metastatic-or-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-05-17",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-03-22",
            "studyFirstSubmitQcDate": "2022-04-20",
            "studyFirstPostDateStruct": {
                "date": "2022-04-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-15",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-16",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Imugene Limited",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is an open-label, dose-escalation, multi-center phase I study evaluating the safety of CF33-hNIS (hNIS - human sodium iodide symporter) administered via two routes of administration, intratumoral (IT) or intravenous (IV), either as a monotherapy or in combination with pembrolizumab in patients with metastatic or advanced solid tumors.",
            "detailedDescription": "CF33-hNIS, a novel chimeric orthopoxvirus, will be administered as a monotherapy or in combination with pembrolizumab to assess the safety and efficacy of the treatment regimens as well as immunological changes in the tumour microenvironment.\n\nPatients eligible for treatment include those with any metastatic or advanced solid tumor who have documented radiological progression per RECIST following at least two prior lines of therapy which may have included treatment with an Immune Checkpoint Inhibitor.\n\nAll enrolled patients will be treated with CF33-hNIS on Day 1 and 8 of Cycle 1 and then on Day 1 of each cycle thereafter. Patients treated with the combination regimen will also received pembrolizumab beginning on Day 1 of each cycle beginning with Cycle 2."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumor",
                "Solid Carcinoma",
                "Solid Tumor, Adult",
                "Metastatic Cancer",
                "Advanced Solid Tumor",
                "Cholangiocarcinoma",
                "Bile Duct Cancer"
            ],
            "keywords": [
                "oncolytic virus"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "CF33-hNIS IT Administration Monotherapy",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Biological: CF33-hNIS"
                    ]
                },
                {
                    "label": "CF33-hNIS IV Administration Monotherapy",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Biological: CF33-hNIS"
                    ]
                },
                {
                    "label": "CF33-hNIS IT Administration in Combination with Pembrolizumab",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Biological: CF33-hNIS",
                        "Biological: Pembrolizumab"
                    ]
                },
                {
                    "label": "CF33-hNIS IV Administration in Combination with Pembrolizumab",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Biological: CF33-hNIS",
                        "Biological: Pembrolizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "CF33-hNIS",
                    "description": "CF33-hNIS is a chimeric orthopoxvirus (oncolytic virus) engineered to express the human sodium iodide symporter (hNIS)",
                    "armGroupLabels": [
                        "CF33-hNIS IT Administration Monotherapy",
                        "CF33-hNIS IT Administration in Combination with Pembrolizumab",
                        "CF33-hNIS IV Administration Monotherapy",
                        "CF33-hNIS IV Administration in Combination with Pembrolizumab"
                    ],
                    "otherNames": [
                        "VAXINIA",
                        "HOV2"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Pembrolizumab",
                    "description": "Pembrolizumab 200mg administrated IV every 3 weeks (Q3W).",
                    "armGroupLabels": [
                        "CF33-hNIS IT Administration in Combination with Pembrolizumab",
                        "CF33-hNIS IV Administration in Combination with Pembrolizumab"
                    ],
                    "otherNames": [
                        "KEYTRUDA\u00ae"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Frequency and severity of Adverse Events of IV and IT CF33-hNIS as a monotherapy or in combination with pembrolizumab",
                    "description": "Adverse events will be graded according to CTCAE v5.0.",
                    "timeFrame": "From first dose of study drug through 30 days following the last dose of study treatment."
                },
                {
                    "measure": "Recommended Phase 2 Dose (RP2D) of CF33-hNIS as a monotherapy or in combination with pembrolizumab",
                    "description": "RP2D determination will be based on evaluation of Dose Limiting Toxicities (DLT) as well as other safety, efficacy and correlative data.",
                    "timeFrame": "From first dose of study drug through 21-42 days following the first dose of study treatment."
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Objective Response Rate (ORR) of CF33-hNIS administered as a monotherapy or in combination with pembrolizumab",
                    "description": "ORR is defined as the proportion of patients in the efficacy population who achieve a radiographic Investigator-assessed confirmed complete response (CR) or partial response (PR), per RECIST v1.1 or confirmed immune complete response (iCR) or immune partial response (iPR) per iRECIST v1.0.",
                    "timeFrame": "Up to 2 years from first dose of study drug."
                },
                {
                    "measure": "Progression-free survival (PFS) of CF33-hNIS administered as a monotherapy or in combination with pembrolizumab.",
                    "description": "PFS, defined as the time from start of treatment to the first documentation of progressive disease (PD) or death from any cause, whichever occurs first.",
                    "timeFrame": "Up to 2 years from first dose of study drug."
                },
                {
                    "measure": "Overall survival (OS) of CF33-hNIS administered as a monotherapy or in combination with pembrolizumab.",
                    "description": "defined as the time from the start of treatment until death due to any cause. Median OS and OS rate at 12 months will be reported.",
                    "timeFrame": "Up to 2 years from first dose of study drug."
                },
                {
                    "measure": "Duration of Response (DOR) of CF33-hNIS administered as a monotherapy or in combination with pembrolizumab.",
                    "description": "DOR is defined as the time from the date a response of PR/iPR or better was first recorded to the date on which progressive disease was first noted or the date of death due to any cause.",
                    "timeFrame": "Up to 2 years from first dose of study drug."
                },
                {
                    "measure": "Disease Control Rate (DCR) of CF33-hNIS administered as a monotherapy or in combination with pembrolizumab.",
                    "description": "DCR is defined as the proportion of patients who achieve an Investigator-assessed confirmed CR/iCR, PR/iPR, or Stable Disease (SD)/immune SD (iSD) per RECIST v1.1 and iRECIST v1.0.",
                    "timeFrame": "Up to 2 years from first dose of study drug."
                },
                {
                    "measure": "To evaluate viral titers of CF33-hNIS",
                    "description": "Viral Plaque Assay (VPA) and polymerase chain reaction (PCR) testing from serum, urine, oral swab, rectal swab, injection site(s) swab and wound dressing swab.",
                    "timeFrame": "Up to 2 years from first dose of study drug."
                },
                {
                    "measure": "To evaluate infection of tumors with CF33-hNIS",
                    "description": "hNIS-based imaging via SPECT technetium-99 (99TC).",
                    "timeFrame": "21 days from first dose of study drug"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "To evaluation antiviral immune activation",
                    "description": "Up regulation of PD-L1 expression as compared to baseline in tumor tissue and circulating tumor cells (CTC).\n\nAnalysis of lymphocyte subsets and cytokine profile compared to baseline.",
                    "timeFrame": "Up to 2 years from first dose of study drug."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent from patient or legally authorized representative\n* Age \u2265 18 years old on the date of consent\n* Any metastatic or advanced solid tumor with documented radiological progression following at least two prior lines of treatment (which may have included prior immune checkpoint inhibitor treatment)\n* ECOG performance status 0 - 2\n* At least one measurable lesion\n* Adequate renal function\n* Adequate liver function\n* Adequate hematologic function\n* Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures\n\nExclusion Criteria:\n\n* Prior treatment with a poxvirus based oncolytic virus.\n* Continuous systemic treatment with either corticosteroids (\\>10 mg daily prednisone equivalents) or other immunosuppressive medications within 4 weeks prior to first dose of study treatment.\n* Prior radiotherapy within 2 weeks of start of study treatment.\n* Active autoimmune disease\n* Prior allogenic tissue/organ transplant or other medical conditions requiring ongoing treatment with immunosuppressive drugs or any condition resulting in a systemic immunosuppressed state\n* Inadequate pulmonary function per Investigator assessment.\n* Uncontrolled brain or other central nervous system (CNS) metastases.\n* History of documented congestive heart failure (New York Heart Association \\[NYHA\\] class III - IV), unstable angina, poorly controlled hypertension, clinically significant valvular heart disease or high-risk uncontrolled arrhythmias",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Lisa Guttman",
                    "role": "CONTACT",
                    "phone": "61 2 9423 0881",
                    "email": "info@imugene.com"
                }
            ],
            "locations": [
                {
                    "facility": "University of Arizona Cancer Center",
                    "status": "RECRUITING",
                    "city": "Tucson",
                    "state": "Arizona",
                    "zip": "85724-5024",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Megan Hodges",
                            "role": "CONTACT",
                            "email": "mhodges@arizona.edu"
                        },
                        {
                            "name": "Abhijeet Kumar, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.22174,
                        "lon": -110.92648
                    }
                },
                {
                    "facility": "Highlands Oncology",
                    "status": "RECRUITING",
                    "city": "Springdale",
                    "state": "Arkansas",
                    "zip": "72762",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Morgan Burns",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Patrick Travis, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.18674,
                        "lon": -94.12881
                    }
                },
                {
                    "facility": "City of Hope Medical Center",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Aruna Parikh",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Dan Li",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "UC San Diego Moores Cancer Center",
                    "status": "RECRUITING",
                    "city": "La Jolla",
                    "state": "California",
                    "zip": "92093-0698",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Katie O'Neil",
                            "role": "CONTACT",
                            "email": "croneil@health.ucsd.edu"
                        },
                        {
                            "name": "Gregory Daniels, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.84727,
                        "lon": -117.2742
                    }
                },
                {
                    "facility": "University of Miami",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33136",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alain Fernandez Marrero",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Jaime Merchan, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "Barbara Ann Karmanos Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48201",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kelly Schneider",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Hirva Mamdani",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "Corewell Health",
                    "status": "RECRUITING",
                    "city": "Grand Rapids",
                    "state": "Michigan",
                    "zip": "49503",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Aaron Cole",
                            "role": "CONTACT",
                            "email": "aaron.cole@corewellhealth.org"
                        },
                        {
                            "name": "Emerson Lim, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.96336,
                        "lon": -85.66809
                    }
                },
                {
                    "facility": "University of Cincinnati",
                    "status": "RECRUITING",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45219",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kayla Webb",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Jennifer Leddon",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                },
                {
                    "facility": "Huntsman Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84112",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Susan Sharry",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Wallace Akerly",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                },
                {
                    "facility": "NEXT Oncology",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Hoda Kassab",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Alexander Spira",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                },
                {
                    "facility": "Tasman Oncology Research",
                    "status": "RECRUITING",
                    "city": "Southport",
                    "state": "Queensland",
                    "zip": "4215",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Molly Phillips",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Andrew Hill, BHB, MBChB, FRACP",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -27.96724,
                        "lon": 153.39796
                    }
                },
                {
                    "facility": "St. Vincent's Hospital",
                    "status": "RECRUITING",
                    "city": "Fitzroy",
                    "state": "Victoria",
                    "zip": "3065",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Jane Mack",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Gavin Wright, MBBS, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -37.79839,
                        "lon": 144.97833
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Imugene Limited (ASX: IMU) is a publicly-listed Australian biotechnology company developing cancer immunotherapies.",
                    "url": "http://www.imugene.com"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000018281",
                    "term": "Cholangiocarcinoma"
                },
                {
                    "id": "D000001650",
                    "term": "Bile Duct Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                },
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000001661",
                    "term": "Biliary Tract Neoplasms"
                },
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000001649",
                    "term": "Bile Duct Diseases"
                },
                {
                    "id": "D000001660",
                    "term": "Biliary Tract Diseases"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "relevance": "LOW"
                },
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M20426",
                    "name": "Cholangiocarcinoma",
                    "asFound": "Cholangiocarcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4936",
                    "name": "Bile Duct Neoplasms",
                    "asFound": "Bile Duct Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M4947",
                    "name": "Biliary Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M4935",
                    "name": "Bile Duct Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4946",
                    "name": "Biliary Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T755",
                    "name": "Bile Duct Cancer",
                    "asFound": "Bile Duct Cancer",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10488",
                    "name": "Iodine",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Micro",
                    "name": "Micronutrients"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}